Sharekhan

Senores Pharmaceuticals Ltd

Fri 9/01/2026,15:54:4 NSE: SENORES

₹ 811.40 -10.00 (-1.22%)
BUY NOW Buy Senores Pharmaceuticals Ltd Stock

Open Free Demat and Trading account in 15 minutes

Home Stock Senores Pharmaceuticals Ltd

Fri 9/01/2026,16:1:0

Senores Pharmaceuticals Ltd

Fri 9/01/2026,15:54:4 | NSE : SENORES

₹ 811.40-10.00 (-1.22%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 815.95

Previous Close

₹ 821.40

Volume

233013

Mkt Cap ( Rs. Cr)

₹3736.79

High

₹ 835.20

Low

₹ 803.60

52 Week High

₹ 876.50

52 Week Low

₹ 435.25

Book Value Per Share

₹ 176.75

Dividend Yield

0.00

Face Value

₹ 10.00

What’s Your Call?

Collective community sentiment on Senores Pharmaceuticals Ltd

Your Vote -

Buy

80.00%

Hold

10.00%

Sell

10.00%

80.00%

10 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

100%

Sell Order Quantity

0%

Bid Price

Qty

811.40

302

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

302

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Option Chain

Analyzes market sentiment, predicts Senores Pharmaceuticals Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Senores Pharmaceutic - Shareholders meeting

    9 Jan 2026, 7:00PM Senores Pharmaceuticals Limited has informed the Exchange regarding Notice of Extraordinary General Meeting scheduled to be held on Saturday, January

  • Senores Pharmaceutic - Notice Of Extra-Ordinary General Meeting Of The Company Scheduled To Be Held On Saturday, January 31,

    9 Jan 2026, 6:58PM Senores Pharmaceuticals Limited has informed the Exchange regarding the Notice of the Extra-Ordinary General Meeting scheduled to be held on Saturday,

  • Senores Pharmaceutic - Outcome of Board Meeting

    7 Jan 2026, 6:13PM Senores Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on January 07, 2026.

  • Senores Pharmaceutic - Board Meeting Outcome for Outcome Of Board Meeting Held On January 07 ,2026

    7 Jan 2026, 6:12PM Senores Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on January 07, 2026

  • Senores Pharmaceutic - Board Meeting Intimation for Considering And Evaluating Proposals For Raising Funds By Way Of Issue Of

    3 Jan 2026, 8:55PM Senores Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/01/2026 ,inter alia, to consi

  • Senores Pharmaceutic - General Updates

    30 Dec 2025, 6:28PM Senores Pharmaceuticals Limited has informed the Exchange regarding revised intimation in respect of earlier intimation dated December 29, 2025 under

  • Senores Pharmaceutic - Revised Intimation Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations

    30 Dec 2025, 6:26PM Senores Pharmaceuticals Limited has informed the Exchange regarding revised intimation in respect of earlier intimation dated December 29, 2025 under

  • Senores Pharmaceutic - General Updates

    29 Dec 2025, 6:48PM Senores Pharmaceuticals Limited has informed the Exchange regarding intimation under Regulation 30 of Securities and Exchange Board of India (Listing

  • Senores Pharmaceutic - Intimation Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disc

    29 Dec 2025, 6:46PM Senores Pharmaceuticals Limited has informed the Exchange regarding intimation under Regulation 30 of Securities and Exchange Board of India (Listing

  • Senores Pharmaceutic - Trading Window

    25 Dec 2025, 4:24PM Senores Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regul

  • Senores Pharmaceutic - Analysts/Institutional Investor Meet/Con. Call Updates

    22 Dec 2025, 5:28PM Senores Pharmaceuticals Limited has informed the Exchange about Transcript of Business Update Call held on December 16, 2025

  • Senores Pharmaceutic - Transcript Of Business Update Call

    22 Dec 2025, 5:26PM Senores Pharmaceuticals Limited has informed the Exchange regarding Business Update Call held on December 16, 2025

  • Senores Pharmaceutic - General Updates

    20 Dec 2025, 2:55PM Senores Pharmaceuticals Limited has informed the Exchange regarding granting of Inter Corporate Loan

  • Senores Pharmaceutic - Intimation Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disc

    20 Dec 2025, 2:50PM Senores Pharmaceuticals Limited has informed the Exchange regarding granting of Inter Corporate Loan

  • Senores Pharmaceutic - Analysts/Institutional Investor Meet/Con. Call Updates

    16 Dec 2025, 4:50PM Senores Pharmaceuticals Limited has informed the Exchange regarding Audio Recording of Business Update Call

  • Senores Pharmaceutic - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    16 Dec 2025, 4:44PM Senores Pharmaceuticals Limited has informed the Exchange regarding Audio Recording of Business Update Call

  • Senores Pharmaceutic - Announcement under Regulation 30 (LODR)-Investor Presentation

    15 Dec 2025, 7:54PM Senores Pharmaceuticals Limited has informed the Exchange regarding Business update presentation

  • Senores Pharmaceutic - Announcement under Regulation 30 (LODR)-Acquisition

    15 Dec 2025, 7:47PM Senores Pharmaceuticals Limited has informed the Exchange regarding Acquisition

  • Senores Pharmaceutic - Press Release

    11 Dec 2025, 9:31PM Senores Pharmaceuticals Limited has informed the Exchange regarding a press release dated December 11, 2025, titled ""Senores Pharmaceuticals, Inc. a

  • Senores Pharmaceutic - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    11 Dec 2025, 9:31PM Senores Pharmaceuticals Limited has informed the exchange regarding Media Release

  • Senores Pharmaceutic - Analysts/Institutional Investor Meet/Con. Call Updates

    5 Dec 2025, 6:10PM Senores Pharmaceuticals Limited has informed the Exchange regarding Analyst/Institutional Investor meet scheduled to be held on December 11, 2025

  • Senores Pharmaceutic - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    5 Dec 2025, 6:08PM Senores Pharmaceuticals Limited has informed the Exchange regarding Analyst/Institutional Investor meet scheduled to be held on December 11, 2025

  • Senores Pharmaceutic - Press Release

    5 Dec 2025, 3:16PM Senores Pharmaceuticals Limited has informed the Exchange regarding a press release dated December 05, 2025, titled ""Senores Pharmaceuticals receives

  • Senores Pharmaceutic - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    5 Dec 2025, 3:16PM Senores Pharmaceuticals Limited has informed the Exchange regarding press release dated December 05, 2025 titled \Senores Pharmaceuticals receives Phi

  • Senores Pharmaceutic - Analysts/Institutional Investor Meet/Con. Call Updates

    13 Nov 2025, 11:10AM Senores Pharmaceuticals Limited has informed the Exchange regarding the transcript of Earnings Conference Call held on Thursday, November 06, 2025 for

  • Senores Pharmaceutic - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

    13 Nov 2025, 11:08AM Senores Pharmaceuticals Limited has informed the Exchange regarding the transcript of Earnings Conference Call held on Thursday, November 06, 2025 for

  • Senores Pharmaceutic - Copy of Newspaper Publication

    7 Nov 2025, 11:08AM Senores Pharmaceuticals Limited has informed the Exchange regarding copy of Newspaper publication for Unaudited Standalone and Consolidated financial

  • Senores Pharmaceutic - Analysts/Institutional Investor Meet/Con. Call Updates

    6 Nov 2025, 7:57PM Senores Pharmaceuticals Limited has informed the Exchange regarding link of Audio recording of Earnings Conference Call for quarter and half year ende

  • Senores Pharmaceutic - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    6 Nov 2025, 7:55PM Senores Pharmaceuticals Limited has informed the Exchange regarding link of Audio recording of Earnings Conference Call for quarter and half year end

  • Senores Pharmaceutic - Monitoring Agency Report

    6 Nov 2025, 5:11PM Senores Pharmaceuticals Limited has informed the Exchange regarding Monitoring Agency Report for the quarter ended September 30, 2025

  • Senores Pharmaceutic - Appointment

    6 Nov 2025, 3:07PM Senores Pharmaceuticals Limited has informed the Exchange regarding changes in the Senior Management Personnel (""SMP"") of the Company

  • Senores Pharmaceutic - Investor Presentation

    6 Nov 2025, 2:18PM Senores Pharmaceuticals Limited has informed the Exchange about Investor Presentation

  • Senores Pharmaceutic - Press Release

    6 Nov 2025, 2:12PM Senores Pharmaceuticals Limited has informed the Exchange regarding a media release dated November 06, 2025, titled ""Strong Financial & Operational P

  • Senores Pharmaceutic - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    6 Nov 2025, 2:12PM Senores Pharmaceuticals Limited has informed the Exchange regarding the media release in relation to the unaudited standalone and consolidated financi

  • Senores Pharmaceutic - Outcome of Board Meeting

    6 Nov 2025, 2:01PM Senores Pharmaceuticals Limited has submitted to the Exchange Outcome of Board Meeting held on November 06, 2025

  • Senores Pharmaceutic - Announcement under Regulation 30 (LODR)-Monitoring Agency Report

    6 Nov 2025, 5:08PM Senores Pharmaceuticals Limited has informed the Exchange regarding Monitoring Agency Report for the quarter ended September 30, 2025

  • Senores Pharmaceutic - Announcement under Regulation 30 (LODR)-Change in Management

    6 Nov 2025, 3:05PM Senores Pharmaceuticals Limited has informed the Exchange regarding changes in the Senior Management Personnel (\SMP\) of the Company

  • Senores Pharmaceutic Q2 net profit zooms 1974.19% at Rs 6.43 cr

    6 Nov 2025, 2:51PM The company reported standalone net profit of Rs 6.43 crore for the quarter ended September 30, 2025 as compared to Rs 0.31 crore in the same period l

  • Senores Pharmaceutic - Announcement under Regulation 30 (LODR)-Investor Presentation

    6 Nov 2025, 2:19PM Senores Pharmaceuticals Limited has informed the Exchange regarding Investor Presentation for Q2 & H1FY26

  • Senores Pharmaceutic - Results For Quarter And Half Year Ended September 30, 2025

    6 Nov 2025, 2:05PM Senores Pharmaceuticals Limited has informed the Exchange the results for Quarter and half year ended September 30,2025

  • Senores Pharmaceutic - Board Meeting Outcome for Outcome Of The Board Meeting Held On November 06, 2025

    6 Nov 2025, 2:00PM Senores Pharmaceuticals Limited has informed the Exchange regarding Outcome of the Board Meeting held on November 06,2025

  • Senores Pharmaceutic - Announcement under Regulation 30 (LODR)-Acquisition

    5 Nov 2025, 6:46PM Senores Pharmaceuticals Limited has informed the Exchange regarding intimation under Regulation 30 of Securities and Exchange Board of India ( Listin

  • Senores Pharmaceutic - General Updates

    5 Nov 2025, 6:44PM Senores Pharmaceuticals Limited has informed the Exchange about Intimation under regulation 30 of Securities and Exchange Board of India (Listing Regu

  • Senores Pharmaceutic - General Updates

    5 Nov 2025, 6:42PM Senores Pharmaceuticals Limited has informed the Exchange regarding updates on USFDA Inspection at Havix Group Inc. d/b/a Aavis Pharmaceuticals, mater

  • Senores Pharmaceutic - Disclosure Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And

    5 Nov 2025, 6:40PM Senores Pharmaceuticals Limited has informed the Exchange regarding updates on USFDA Inspection at Havix Group Inc. d/b/a Aavis Pharmaceuticals, mater

  • Senores Pharmaceutic - Analysts/Institutional Investor Meet/Con. Call Updates

    29 Oct 2025, 6:21PM Senores Pharmaceuticals Limited has informed the Exchange regarding Earnings Conference Call for Q2FY26 scheduled to be held on November 06, 2025 at 0

  • Senores Pharmaceutic - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    29 Oct 2025, 6:18PM Senores Pharmaceuticals Limited has informed the Exchange regarding Earnings Conference Call for Q2FY26 scheduled to be held on November 06, 2025 at 0

  • Senores Pharmaceutic - Board Meeting Intimation for Considering And Approving The Un-Audited Standalone And Consolidated Fina

    29 Oct 2025, 6:13PM Senores Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/11/2025 ,inter alia, to consi

  • Senores Pharmaceutic has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2025

    11 Oct 2025, 7:05AM As of September 2025, 45.80% is owned by Promoters and 54.20% by Public. <p align=justify> Among Promoters holding, Indian Promoters holds 39.52% and

  • Senores Pharmaceuticals Ltd

    12 Dec 2025 , 10:37AM Senores pharma: launches Deferiprone Tablets USP (500mg & 1000mg) in the U.S., bioequivalent to Ferriprox. Dr. Reddy’s Laboratories Inc. to market the product in the U.S. - Deferiprone Tablets had ~$70M in U.S. sales for the 12 months ending October 2025. Positive

  • Senores Pharmaceuticals

    6 Nov 2025 , 1:19PM Senores Pharmaceuticals : The company reported two major developments – Its wholly owned subsidiary, Senores Pharmaceuticals Inc. (SPI) acquired 51% stake in Zoraya Pharmaceuticals LLC, Delaware, USA through subscription of membership interest.With this move, Zoraya has become a step-down subsidiary of the Company and bolsters its operations as well as product development strengths in the US. Secondly, its material subsidiary, Havix Group Inc. D/B/A Aavis Pharmaceuticals, based in Georgia, USA, has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration after a successful inspection in July 2025. The inspection concluded with three minor observations, all of which have been resolved to the satisfaction of the USFDA, marking the closure of the inspection.

  • Senores Pharmaceuticals Ltd

    13 Aug 2025 , 8:59AM Senores Pharmaceuticals, through its US subsidiary, has signed an agreement to acquire two USFDA-approved ANDAs from Teva Pharmaceuticals USA. The US market opportunity is estimated at ~USD 38 mn (IQVIA, Dec 2024) and ~USD 120 mn (Symphony, Jun 2025). The acquisition will be funded from IPO proceeds, in line with the stated IPO objectives.

  • Senores Pharmaceuticals acquires ANDA for Roflumilast

    21 Feb 2025 , 12:36PM Senores Pharmaceuticals acquires ANDA for Roflumilast 250 mcg and 500 mcg tablets
Load More
Show Less

Key fundamentals

Evaluate the intrinsic value of Senores Pharmaceuticals Ltd stock 

Name March-25 March-24 March-23 March-22
Assets 801.93 260.871 99.332 48.2313
Liabilities 801.93 260.871 99.332 48.2313
Equity 46.05 30.505 9.818 8.7422
Gross Profit -7.28 -0.062 -1.78 0.9342
Net Profit 3.69 0.814 1.199 0.293
Cash From Operating Activities -20.4 -62.818 -43.414 -12.1977
NPM(%) 9.57 2.39 9.68 1.84
Revenue 38.54 34.006 12.382 15.8508
Expenses 45.82 34.068 14.162 14.9166
ROE(%) 0.45 0.09 0.14 0.03

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day

Peers

Other companies within the same industry or sector that are comparable to Senores Pharmaceuticals Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 731.10 -2.46 0.00 464.22 301.39 0.68
Lotus Eye Hospital and Institute Ltd 111.58 -3.38 348.69 1691.57 3.55 0.00
Vaishali Pharma Ltd 8.57 1.06 0.00 10611.79 3.13 0.00
Astec Lifesciences Ltd 639.40 -3.82 0.00 1595.19 -604.77 0.00

Company Info

Our Company was originally incorporated as "Senores Pharmaceuticals Private Limited" a private limited company under the Companies Act, 2013 through certificate of incorporation dated December 26, 2017, issued by the Registrar of Companies, Central Registration Centre.The name of the Company was thereafter changed to "Senores Pharmaceuticals Limited" upon conversion to a public limited company pursuant to a Board resolution dated August 1, 2023, a special resolution passed in the extraordinary general meeting of the Shareholders held on August 24, 2023 and the approval of the central government dated September 4, 2023, and consequently a fresh certificate of incorporation dated September 4, 2023, was issued by the RoC to reflect the change in name.Major Events and Milestones:2021- Incorporated a wholly owned subsidiary, Senores Pharmaceuticals Inc in the US.2021- Entered into a new segment of API with acquisition of Ratnagene Lifescience Private Limited 2022 - Started the domestic business with a launch of the critical care injectables 2024 - Launched first CMO product in the US with Jubilant Cadista.

Our Company was originally incorporated as "Senores Pharmaceuticals Private Limited" a private limited company under the Companies Act, 2013 through certificate of incorporation dated December 26, 2017, issued by the Registrar of Companies, Central Registration Centre.The name of the Company was thereafter changed to "Senores Pharmaceuticals Limited" upon conversion to a public limited company pursuant to a Board resolution dated August 1, 2023, a special resolution passed in the extraordinary general meeting of the Shareholders held on August 24, 2023 and the approval of the central government dated September 4, 2023, and consequently a fresh certificate of incorporation dated September 4, 2023, was issued by the RoC to reflect the change in name.Major Events and Milestones:2021- Incorporated a wholly owned subsidiary, Senores Pharmaceuticals Inc in the US.2021- Entered into a new segment of API with acquisition of Ratnagene Lifescience Private Limited 2022 - Started the domestic business with a launch of the critical care injectables 2024 - Launched first CMO product in the US with Jubilant Cadista.

Read More

Parent Organisation

Senores Pharmaceuticals Ltd.

Founded

26/12/2017

Managing Director

Mr.Swapnil Jatinbhai Shah

NSE Symbol

SENORESEQ

FAQ

The current price of Senores Pharmaceuticals Ltd is ₹ 811.40.

The 52-week high for Senores Pharmaceuticals Ltd is ₹ 835.20 and the 52-week low is ₹ 803.60.

The market capitalization of Senores Pharmaceuticals Ltd is currently ₹ 3736.79. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Senores Pharmaceuticals Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Senores Pharmaceuticals Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Senores Pharmaceuticals Ltd shares.

The CEO of Senores Pharmaceuticals Ltd is Mr.Swapnil Jatinbhai Shah, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT